Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rowe

Showing results (111-120 of 1,408) with videos related to

Pageof 141
Sort By:
Leukemia|June 10, 2005
Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?J M Rowe
Best Practice & Research. Clinical Haematology|March 7, 2006
Preface: significant advances in the biology and therapy of AML over the past four decadesJacob M Rowe
Lancet (London, England)|March 22, 1997
Multidrug-resistance gene employed to advantageP M Rowe
Best Practice & Research. Clinical Haematology|December 4, 2012
The impact of mutational profiling on AML prognosisJacob M Rowe
Best Practice & Research. Clinical Haematology|December 5, 2009
Advances and controversies in the biology and therapy of acute leukaemia and myelodysplasiaJacob M Rowe
Best Practice & Research. Clinical Haematology|December 5, 2009
Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)?Jacob M Rowe
Lancet (London, England)|July 10, 1993
US AIDS information serviceP M Rowe
Lancet (London, England)|March 12, 1999
What is all the hullabaloo about endostatin?P M Rowe
Best Practice & Research. Clinical Haematology|November 30, 2019
Will new agents impact survival in AML?Jacob M Rowe
The American Journal of Medical Technology|February 1, 1983
Clinical and laboratory features of the myeloid and lymphocytic leukemiasJ M Rowe
Pageof 141

Showing results (111-120 of 1,408) with videos related to

Sort By:
Pageof 141
Leukemia|June 10, 2005
Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?J M Rowe
Best Practice & Research. Clinical Haematology|March 7, 2006
Preface: significant advances in the biology and therapy of AML over the past four decadesJacob M Rowe
Lancet (London, England)|March 22, 1997
Multidrug-resistance gene employed to advantageP M Rowe
Best Practice & Research. Clinical Haematology|December 4, 2012
The impact of mutational profiling on AML prognosisJacob M Rowe
Best Practice & Research. Clinical Haematology|December 5, 2009
Advances and controversies in the biology and therapy of acute leukaemia and myelodysplasiaJacob M Rowe
Best Practice & Research. Clinical Haematology|December 5, 2009
Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)?Jacob M Rowe
Lancet (London, England)|July 10, 1993
US AIDS information serviceP M Rowe
Lancet (London, England)|March 12, 1999
What is all the hullabaloo about endostatin?P M Rowe
Best Practice & Research. Clinical Haematology|November 30, 2019
Will new agents impact survival in AML?Jacob M Rowe
The American Journal of Medical Technology|February 1, 1983
Clinical and laboratory features of the myeloid and lymphocytic leukemiasJ M Rowe
Pageof 141